{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-21-001387","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.782978+00:00","generated_at":"2026-06-28T10:02:42.930909+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Edgewise reports Q3 net loss $12.9M; positive Phase 1 MAD data for EDG-5506","bullets":["Cash, cash equivalents and marketable securities of $290M as of Sept 30, 2021.","R&D expenses $9.9M (Q3 2021) vs $3.2M (Q3 2020), increase due to Phase 1 trial and headcount.","Net loss $12.9M ($0.26/share) compared to $3.6M in Q3 2020.","Positive EDG-5506 Phase 1 MAD topline: well tolerated, target engagement, no effect on voluntary strength or cardiac myosin.","First BMD patients dosed in Phase 1b; Phase 2 trials in BMD and DMD expected to start in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-21-001387","json":"https://secwatch.observer/filing/0001157523-21-001387.json","markdown":"https://secwatch.observer/filing/0001157523-21-001387.md","text":"https://secwatch.observer/filing/0001157523-21-001387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000115752321001387/0001157523-21-001387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000115752321001387/a52527144.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:02:42.930909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}